EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Serum Beta-Secretase 1 Activity Is a Potential Marker for the Differential Diagnosis between Alzheimer’s Disease and Frontotemporal Dementia: A Pilot Study

Claudia Saraceno iD, Carlo Cervellati iD, Alessandro Trentini iD, Daniela Crescenti iD, Antonio Longobardi iD, Andrea Geviti iD, Natale Salvatore Bonfiglio, Sonia Bellini iD, Roland Nicsanu iD, Silvia Fostinelli iD, Gianmarco Mola, Raffaella Riccetti und 5 weitere

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25158354 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Claudia Saraceno und 16 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, 25125 Brescia, Italy. Hauptthemen laut MEDLINE: Alzheimer Disease, Frontotemporal Dementia, Amyloid Precursor Protein Secretases, Biomarkers. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Health, Italy.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer’s disease (AD) and frontotemporal dementia (FTD) are the two major neurodegenerative diseases causing dementia. Due to similar clinical phenotypes, differential diagnosis is challenging without specific biomarkers. Beta-site Amyloid Precursor Protein cleaving enzyme 1 (BACE1) is a β-secretase pivotal in AD pathogenesis. In AD and mild cognitive impairment subjects, BACE1 activity is increased in brain/cerebrospinal fluid, and plasma levels appear to reflect those in the brain. In this study, we aim to evaluate serum BACE1 activity in FTD, since, to date, there is no evidence about its role. The serum of 30 FTD patients and 30 controls was analyzed to evaluate (i) BACE1 activity, using a fluorescent assay, and (ii) Glial Fibrillary Acid Protein (GFAP) and Neurofilament Light chain (NfL) levels, using a Simoa kit. As expected, a significant increase in GFAP and NfL levels was observed in FTD patients compared to controls. Serum BACE1 activity was not altered in FTD patients. A significant increase in serum BACE1 activity was shown in AD vs. FTD and controls. Our results support the hypothesis that serum BACE1 activity is a potential biomarker for the differential diagnosis between AD and FTD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseFrontotemporal DementiaAmyloid Precursor Protein SecretasesBiomarkersAspartic Acid EndopeptidasesGlial Fibrillary Acidic ProteinHumansDiagnosis, DifferentialFemaleMaleAgedPilot ProjectsMiddle AgedNeurofilament ProteinsCase-Control Studies

Stichwörter der Autor:innen

Alzheimer’s diseaseBACE1GFAPNfLbiomarkerdifferential diagnosisfrontotemporal dementiaserum

Substanzen

Amyloid Precursor Protein SecretasesBiomarkersBACE1 protein, humanAspartic Acid EndopeptidasesGlial Fibrillary Acidic ProteinNeurofilament Proteinsneurofilament protein L

Autor:innen und Institutionen

  • Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, 25125 Brescia, Italy.
  • Department of Translational Medicine and for Romagna, University of Ferrara, 44121 Ferrara, Italy.
  • Department of Environmental and Prevention Sciences, University of Ferrara, 44121 Ferrara, Italy.
  • Service of Statistics, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, 25125 Brescia, Italy.
  • MAC-Memory Clinic and Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, 25125 Brescia, Italy.
  • Alzheimer's Rehabilitation Operative Unit, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, 25125 Brescia, Italy.

ORCID-Profile: Claudia Saraceno, Carlo Cervellati, Alessandro Trentini, Daniela Crescenti, Antonio Longobardi, Andrea Geviti, Sonia Bellini, Roland Nicsanu, Silvia Fostinelli, Roberta Ghidoni

Förderung

  • Italian Ministry of Health, Italy

Zitieren

APA

Saraceno, C., Cervellati, C., Trentini, A., Crescenti, D., Longobardi, A., Geviti, A., Bonfiglio, N. S., Bellini, S., Nicsanu, R., Fostinelli, S., Mola, G., Riccetti, R., Moretti, D. V., Zanetti, O., Binetti, G., Zuliani, G., & Ghidoni, R. (2024). Serum Beta-Secretase 1 Activity Is a Potential Marker for the Differential Diagnosis between Alzheimer’s Disease and Frontotemporal Dementia: A Pilot Study. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25158354

Vancouver

Saraceno C, Cervellati C, Trentini A, Crescenti D, Longobardi A, Geviti A, et al. Serum Beta-Secretase 1 Activity Is a Potential Marker for the Differential Diagnosis between Alzheimer’s Disease and Frontotemporal Dementia: A Pilot Study. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25158354

BibTeX
@article{Saraceno2024,
  author = {Saraceno, Claudia and Cervellati, Carlo and Trentini, Alessandro and Crescenti, Daniela and Longobardi, Antonio and Geviti, Andrea and Bonfiglio, Natale Salvatore and Bellini, Sonia and Nicsanu, Roland and Fostinelli, Silvia and Mola, Gianmarco and Riccetti, Raffaella and Moretti, Davide Vito and Zanetti, Orazio and Binetti, Giuliano and Zuliani, Giovanni and Ghidoni, Roberta},
  title = {Serum Beta-Secretase 1 Activity Is a Potential Marker for the Differential Diagnosis between Alzheimer’s Disease and Frontotemporal Dementia: A Pilot Study},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25158354}
}
Kostenlos starten →